Farmacosmo's earnings have been declining at an average annual rate of -54.8%, while the Specialty Retail industry saw earnings declining at 5.7% annually. Revenues have been growing at an average rate of 1.8% per year.
Key information
-54.78%
Earnings growth rate
-46.93%
EPS growth rate
Specialty Retail Industry Growth
4.13%
Revenue growth rate
1.79%
Return on equity
-86.99%
Net Margin
-7.89%
Last Earnings Update
31 Dec 2025
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Farmacosmo makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DB:ZJ1 Revenue, expenses and earnings (EUR Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
56
-4
0
0
30 Sep 25
58
-5
0
0
30 Jun 25
59
-5
0
0
31 Mar 25
62
-4
0
0
31 Dec 24
64
-3
0
0
30 Sep 24
66
-3
0
0
30 Jun 24
68
-4
0
0
31 Mar 24
70
-4
1
0
31 Dec 23
72
-3
1
0
30 Sep 23
72
-2
0
0
30 Jun 23
72
-1
0
0
31 Mar 23
69
-1
0
0
31 Dec 22
67
-1
0
0
30 Sep 22
66
-1
0
0
30 Jun 22
64
0
0
0
31 Mar 22
61
0
0
0
31 Dec 21
58
0
0
0
30 Sep 21
56
1
0
0
31 Dec 20
44
0
0
0
31 Dec 19
24
0
0
0
Quality Earnings: ZJ1 is currently unprofitable.
Growing Profit Margin: ZJ1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZJ1 is unprofitable, and losses have increased over the past 5 years at a rate of 54.8% per year.
Accelerating Growth: Unable to compare ZJ1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZJ1 is unprofitable, making it difficult to compare its past year earnings growth to the Specialty Retail industry (-0.3%).
Return on Equity
High ROE: ZJ1 has a negative Return on Equity (-86.99%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/17 18:33
End of Day Share Price
2026/06/17 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Farmacosmo S.p.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.